Caplin Steriles gets USFDA approval for potassium phosphates injection

AI boom, screen overload quietly stealing India’s sleep, new survey warns

FDA nod to first treatment for rare genetic brain disorder

The approval comes after a systematic review of published literature

Pfizer’s experimental atopic dermatitis drug shows strong Phase 2 results

The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75

GAIA and Daiichi Sankyo Europe join forces to launch groundbreaking digital therapeutic for heart health

Germany will be the first launch market

Novo Nordisk strikes deal with Hims & Hers, expands access to Ozempic & Wegovy in US

Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms

FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials

AbbVie reports promising early results for novel obesity therapy ABBV-295

ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks

Roche’s Gazyva shows breakthrough results in Lupus phase III trial

Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints

argenx reports breakthrough Phase 3 results for VYVGART in ocular myasthenia gravis

The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4